



THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF: Chen et al : CASE NO.: PH-7211  
SERIAL NO.: 10/043,627 : ART UNIT: 1614  
FILED: January 9, 2002 : EXAMINER: Unknown  
FOR: 1,1-Disubstituted Cyclic Inhibitors of Matrix Metalloproteases and TNF-Alpha

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

Assistant Commissioner for Patents  
Washington, D.C. 20231

JUL 19 2002

TECH CENTER 1600/2900

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ( X ) In accordance with §1.97(b), since this Supplemental Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is set forth below.
  - ( ) The fee of \$240.00 as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1)

Attached is the PCT Search Report which lists one U.S. reference. This U.S. reference is noted on PTO Form 1449, also attached.

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

Respectfully submitted,

*Jing S. Belfield*

Jing S. Belfield

Agent for Applicants

Registration No. 45,914

Telephone: 302-467-5262

DATE: 7/11/2002

Bristol-Myers Squibb Pharma Company  
P. O. Box 4000  
Princeton, NJ 08543-4000

COPY OF PAPERS  
ORIGINALLY FILED



COPY OF PAPERS  
ORIGINALLY FILED

PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certificate of Mailing under 37 CFR 1.8

In the Application of: Chen et al

CASE NO.: PH-7211

APPLICATION NO.: 10/043,627

GROUP ART UNIT: 1614

FILED: JANUARY 9, 2002

EXAMINER: UNKNOWN

FOR: 1,1-disubstituted cyclic inhibitors of matrix metallo-proteases and tnf-alpha

I hereby certify that this correspondence a **Supplemental Information Disclosure Statement, PTO Form 1449, References and Postcard** are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

On

7-11-02

Date

RECEIVED

JUL 19 2002

TECH CENTER 1600/2900

Signature

Diane C. Pickering/Depositor

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.